Product Portfolio Exposed To Generic Competition Hurts Sanofi's Q311 Results

BMI View: While Sanofi's share price movements have aligned with that of the pharma 20 index over the past 12 months, BMI believes that over the next 12 months investor perception regarding the company will drop despite its focus on executing its strategic priorities. BMI does not expect the introduction of price erosion mechanisms in Europe to end now, which will result in deflation for pharmaceutical products across the region in 2011, affecting Sanofis revenue-earning opportunities. Sanofi is facing a steep drop in sales in coming years. A number of generic drugmakers have already launched copies of the company's top-selling

To read the full article, please choose one of the following options: